Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched a suite of antibiotic products for injection.
Ampicillin for Injection, USP
Ampicillin and Sulbactam for Injection, USP
Nafcillin for Injection, USP
Penicillin G Potassium for Injection, USP
Piperacillin and Tazobactam for Injection, USP
Combined, these products generated U.S. sales of approximately $175M for the twelve months ended September 30, 2024, representing a meaningful opportunity in the generic injectables market.
“The launch of these five antibiotic products further strengthens Avenacy’s foundational portfolio of high-usage, critical injectable products. I am proud of how swiftly this team has worked to successfully bring 20 important medications to the U.S. market, ”said Jeff Yordon, Co-Founder and CEO of Avenacy. “As we continue to focus on accelerating our growth, these antibiotic products will enable us to deepen our commercial presence in both the hospital and long-term/home health settings. With our growing antibiotic portfolio, we are well-positioned to drive continued market expansion that supports our long-term strategic objectives.”
In line with Avenacy’s mission to champion patient safety and streamline patient care, all five antibiotic products will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping all five antibiotics to wholesale partners next week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Product Information for Launched Antibiotics
Ampicillin for Injection, USP
Ampicillin for Injection, USP is a therapeutic equivalent generic for Omnipen-N® approved by the U.S. Food and Drug Administration. Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions:
It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Indicated surgical procedures should be performed.
Ampicillin for Injection, USP had U.S. sales of approximately $3 million for the twelve months ending in September 2024.1 Avenacy’s Ampicillin for Injection, USP is available as 10 g Pharmacy Bulk Bottles.
Ampicillin and Sulbactam for Injection, USP
Ampicillin and Sulbactam for Injection, USP is a therapeutic equivalent generic for Unasyn® approved by the U.S. Food and Drug Administration. Ampicillin and Sulbactam for Injection, USP, is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below:
Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli*, Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis*, Bacteroides fragilis*, Enterobacter spp.*, and Acinetobacter calcoaceticus*.
NOTE: For information on use in pediatric patients see PRECAUTIONS-PEDIATRIC USE and CLINICAL STUDIES sections.
Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*
Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli*, and Bacteroides spp.* (including B. fragilis*).
About Avenacy:
Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.
For more information, please visit http://www.avenacy.com/.